Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease
July 07 2022 - 06:00AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercializing
oral immunotherapeutics for the prevention and treatment of gut
mediated pathogens, is pleased to announce that it has received
notification of the Intent to Grant a European Patent for
compositions and methods for the treatment and/or prophylaxis of
Clostridioides difficile associated disease.
Notification of the intent to grant European
Patent 14784945.9, entitled “Methods and Compositions for the
treatment and/or prophylaxis of Clostridium difficile associated
disease,” was received from the European Patent Office.
The European registration once formally granted
will add to Immuron's patent position for compositions and methods
for the treatment and/or prophylaxis of Clostridioides difficile
associated disease in Australia, New Zealand and the United
States.
Clostridioides difficile (previously known as
Clostridium difficile) infection (CDI) is a disease of the large
intestine caused by toxins produced by the spore forming bacterium
Clostridioides difficile. CDI can also result in serious disease
complications including bowel perforation, toxic megacolon and
sepsis, and it can prove fatal in the most severe cases. In recent
years, increases in the frequency and severity of CDI have been
observed worldwide, as well as an increased risk of
community-associated CDI, and CDI in persons previously thought to
be low risk. It is estimated that CDI affects up to 1.2% of
hospitalized patients in the United States, representing an
estimated cost of USD 4.8 billion per year (source: CDC). In
Europe, the estimated cost is approximately 3 billion per year,
which is likely to increase concomitantly with a more elderly
society; more than 134 million Europeans will be >65 years by
2050.
This release has been authorised by the
directors of Immuron Limited.
COMPANY
CONTACT:Steven
LydeamoreChief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com |
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of infectious
diseases.
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Mar 2023 to Mar 2024